tiprankstipranks
Greenrise Global Brands Inc (TSE:XCX)
:XCX

Greenrise Global Brands Inc (XCX) AI Stock Analysis

Compare
2 Followers

Top Page

TSE:XCX

Greenrise Global Brands Inc

(XCX)

Select Model
Select Model
Select Model
Neutral 41 (OpenAI - 5.2)
Rating:41Neutral
Price Target:
C$0.01
▲(0.00% Upside)
Action:UpgradedDate:12/30/25
The score is driven primarily by very weak financial performance (recurring losses, negative equity, and a thin asset base relative to debt) and pressured/volatile cash generation. Valuation is also unattractive to assess due to negative earnings and no dividend data, while technicals cannot be evaluated with the indicators provided.
Positive Factors
Strategic Partnerships
Strategic partnerships enhance distribution capabilities and market penetration, potentially driving long-term revenue growth and brand recognition.
Negative Factors
High Leverage
High leverage and negative equity pose significant financial risks, limiting operational flexibility and increasing vulnerability to economic downturns.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic Partnerships
Strategic partnerships enhance distribution capabilities and market penetration, potentially driving long-term revenue growth and brand recognition.
Read all positive factors

Greenrise Global Brands Inc (XCX) vs. iShares MSCI Canada ETF (EWC)

Greenrise Global Brands Inc Business Overview & Revenue Model

Company Description
Greenrise Global Brands Inc., through its subsidiaries, operates as a pharmaceutical supplier of medical cannabis products to pharmacies in Germany. It offers a range of CBD products consisting of tinctures, sprays, oils, and skincare products thr...
How the Company Makes Money
Greenrise Global Brands Inc generates revenue primarily through the sale of its cannabis and hemp-based products. These products are sold through various channels, including direct-to-consumer sales, retail partnerships, and online platforms. The ...

Greenrise Global Brands Inc Financial Statement Overview

Summary
Financial health is very weak: revenue is minimal/inconsistent (including multiple years at $0), EBIT and net income are persistently negative (net loss -$1.08M in 2024), equity is negative (-$2.70M in 2024), and assets are extremely small ($93.5k) versus debt ($2.62M). Cash flow improved versus earlier heavy burn but reverted to negative in 2024 (FCF -$176k), keeping funding/solvency risk elevated.
Income Statement
12
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
18
Very Negative
BreakdownTTMMar 2025Mar 2024Jun 2023Mar 2022Mar 2021
Income Statement
Total Revenue0.000.000.000.00452.87K105.20K
Gross Profit0.000.000.000.0043.32K-153.00
EBITDA-597.32K-411.10K0.00-744.80K-2.60M-2.06M
Net Income-807.54K-1.08M-2.32M-3.64M-2.11M
Balance Sheet
Total Assets2.13K93.53K441.82K1.25M252.94K371.56K
Cash, Cash Equivalents and Short-Term Investments2.13K13.53K31.53K-619.68K27.45K60.45K
Total Debt4.47M2.62M2.80M3.15M1.90M1.08M
Total Liabilities4.72M2.79M3.06M3.56M2.26M1.34M
Stockholders Equity-4.71M-2.70M-2.61M-2.32M-2.00M-972.61K
Cash Flow
Free Cash Flow-132.37K-176.13K199.35K-1.08M-1.95M-1.88M
Operating Cash Flow-132.37K-176.13K199.35K-1.08M-1.89M-1.83M
Investing Cash Flow134.97K60.40K387.50K-531.00K-63.15K45.43K
Financing Cash Flow-25.86K97.73K-534.73K1.51M1.92M1.63M

Greenrise Global Brands Inc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
41
Neutral
C$258.28K-1.175.70%-406.12%
C$272.55K-0.01
46
Neutral
C$463.91K-1.336.61%
C$420.72K-0.31
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:XCX
Greenrise Global Brands Inc
0.01
-0.01
-50.00%
TSE:GHG
Global Hemp
0.02
0.00
0.00%
TSE:LOWL
Lowell Farms
0.02
-0.03
-62.50%
TSE:CNTR
CENTR Brands
0.04
-0.01
-20.00%
TSE:XBRA
Xebra Brands Ltd.
0.01
-0.07
-87.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 30, 2025